<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04674709</url>
  </required_header>
  <id_info>
    <org_study_id>AH-O4X-11-2020-01</org_study_id>
    <nct_id>NCT04674709</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Pharmacokinetics of Oleander 4X in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of Oleander 4X in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avila Herbals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avila Herbals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The homeopathic medicine, Oleander 4X HPUS is indicated for temporary relief of symptoms&#xD;
      associated with flu, such as muscle or body aches, headaches, chills and fever, cough, and&#xD;
      congestion. The primary purpose of this study is to assess the safety of Oleander 4X HPUS in&#xD;
      health male and female subjects compared to a placebo. This is a randomized, double blind,&#xD;
      placebo-controlled Phase I Proof of Concept clinical trial to evaluate the safety and&#xD;
      efficacy of OLEANDER 4X HPUS in Healthy Volunteers. Briefly, 45 Healthy volunteers who meet&#xD;
      the eligibility criteria and agree to participation in the study will be placed on 1.0 mL of&#xD;
      OLEANDER 4X HPUS, four-to-twelve times per day for seven days. For the pharmacokinetics study&#xD;
      (cohorts 4-6), participants will take OLEANDER 4X HPUS at a prescribed dose one time.&#xD;
&#xD;
      The aim of the present study is to evaluate the safety of OLEANDER 4X HPUS. This real-world&#xD;
      cohort provides a unique opportunity to study this medicine. This protocol outlines a study&#xD;
      involving Healthy volunteers. Up to 45 volunteers will be recruited in specific health&#xD;
      systems in the USA.&#xD;
&#xD;
      Second ARM, sub-study: As a second arm of this study, a random double blind,&#xD;
      placebo-controlled pharmacokinetics study in healthy volunteers. Briefly, 15 healthy&#xD;
      volunteers who meet the same eligibility criteria and agree to participation in the study&#xD;
      will be placed on one, two, or 4 doses (1 mL per dose) of OLEANDER 4X HPUS one time.&#xD;
&#xD;
      This is effectively three ascending doses in 4 subjects on OLEANDER 4X HPUS, compared to the&#xD;
      placebo (1 subject).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the present study is to evaluate the safety of OLEANDER 4X HPUS. This protocol&#xD;
      outlines a study involving Healthy volunteers. Up to 45 volunteers will be recruited in the&#xD;
      USA.&#xD;
&#xD;
      Second ARM, sub-study: As a second arm of this study, a random double blind,&#xD;
      placebo-controlled pharmacokinetics study in healthy volunteers. Briefly, 15 healthy&#xD;
      volunteers who meet the same eligibility criteria and agree to participation in the study&#xD;
      will be placed on one, two, or 4 doses (1 mL per dose) of OLEANDER 4X HPUS one time.&#xD;
&#xD;
      This is effectively three ascending doses in 4 subjects on OLEANDER 4X HPUS, compared to the&#xD;
      placebo (1 subject).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 24, 2020</start_date>
  <completion_date type="Anticipated">January 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a randomized, double-blind, placebo-controlled Phase I study that will investigate the safety and efficacy of OLEANDER 4X HPUS in Healthy Volunteers.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Triple: Triple (Participant, Care provider, Investigator)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events, serious event, and any related reactions as assessed by CTCAE v5.0.</measure>
    <time_frame>1-7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>proportion of subjects undergoing DLT events</measure>
    <time_frame>1-7 days</time_frame>
    <description>Safety evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetic parameters - AreaUnderCUrve (AUCt) [Time Frame: 24 hours]</measure>
    <time_frame>0-24 hours</time_frame>
    <description>AUCt plasma concentration of oleander (using Oleandrin as the marker) during 24 hours after administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>half-life (t1/2)</measure>
    <time_frame>0-24 hours</time_frame>
    <description>half-life (t1/2) of oleander extract (using Oleandrin as the marker) during 24 hours after administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maximum and minimum plasma concentration</measure>
    <time_frame>0-24 hours</time_frame>
    <description>maximum and minimum plasma concentration of oleander extract (using Oleandrin as the marker) during 24 hours after administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total body clearance (Cltot)</measure>
    <time_frame>0-24 hours</time_frame>
    <description>total body clearance (Cltot) of oleander extract (using Oleandrin as the marker) during 24 hours after administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Flu-like Symptoms</condition>
  <arm_group>
    <arm_group_label>Safety of Oleander 4X HPUS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>: To evaluate the clinical safety of OLEANDER 4X HPUS in healthy volunteers relative to the control arm (placebo group).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pharmacokinetics evaluation of Oleander 4X HPUS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To evaluate the pharmacokinetics of OLEANDER 4X HPUS versus placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oleander 4X - single</intervention_name>
    <description>Cohort 1 receive 4 doses of Oleander 4X in a 24-hour period for a period of seven days.</description>
    <arm_group_label>Pharmacokinetics evaluation of Oleander 4X HPUS</arm_group_label>
    <arm_group_label>Safety of Oleander 4X HPUS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oleander 4X - double</intervention_name>
    <description>Cohort 2 receive 2 doses of either active drug or placebo 4 times per day in a 24-hour period for a period of seven days.</description>
    <arm_group_label>Pharmacokinetics evaluation of Oleander 4X HPUS</arm_group_label>
    <arm_group_label>Safety of Oleander 4X HPUS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oleander 4X - quadruple</intervention_name>
    <description>Cohort 3 receive 4 doses of either active drug four times per day in a 24-hour period for a period of seven days.</description>
    <arm_group_label>Pharmacokinetics evaluation of Oleander 4X HPUS</arm_group_label>
    <arm_group_label>Safety of Oleander 4X HPUS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo group receives 4 doses of placebo in a 24-hour period for a period of 7 days</description>
    <arm_group_label>Pharmacokinetics evaluation of Oleander 4X HPUS</arm_group_label>
    <arm_group_label>Safety of Oleander 4X HPUS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy Volunteers.&#xD;
&#xD;
          -  Subjects with no symptoms of respiratory illness such as fever, rhinorrhea, mild&#xD;
             cough, sore throat, headache, fatigue, muscle pain, and malaise but with no shortness&#xD;
             of breath.&#xD;
&#xD;
          -  Male or non-pregnant female adult &gt; 18 to 65 years of age at time of enrollment to&#xD;
             include all races and ethnic minorities.&#xD;
&#xD;
          -  Agree to the collection of blood specimens (for the pharmacokinetics study).&#xD;
&#xD;
          -  Willingness of study participant to provide informed consent and accept randomization&#xD;
             to any assigned treatment arm.&#xD;
&#xD;
          -  Must agree not to enroll in another study of an investigational agent prior to Day 28&#xD;
             of study, unless hospitalized.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Signs of any respiratory distress or pulmonary infection defined as the need for&#xD;
             non-invasive or invasive mechanical ventilator support, ECMO or shock requiring&#xD;
             vasopressor support.&#xD;
&#xD;
          -  Subjects with risk factors for severe disease (e.g. hypertension, diabetes, pulmonary,&#xD;
             cardiovascular, renal, hepatic, neurologic disease or immune compromise, obesity, and&#xD;
             pregnancy).&#xD;
&#xD;
          -  Any previous history of clinically significant cardiovascular disease, including&#xD;
             ventricular arrhythmias.&#xD;
&#xD;
          -  Current use of cardiac glycosides or a known allergic reaction to cardiac glycosides&#xD;
             or compounds of similar chemical or biologic composition.&#xD;
&#xD;
          -  Any risk factors that can lead to severe COVID-19 including uncontrolled diabetes,&#xD;
             hypertension, and systemic diseases including hepatic disease and renal insufficiency.&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Participation in any other clinical trial of an experimental treatment for COVID-19.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theresa G Obiso, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Avila Herbals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard J Obiso, PhD</last_name>
    <phone>800-936-0197</phone>
    <email>rik@obisoco.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dr. William Ball offices</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Ball, MD</last_name>
      <phone>540-772-1006</phone>
      <email>roanokefamilymed@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Flu-like symptoms</keyword>
  <keyword>Avila Herbals</keyword>
  <keyword>Phoenix Biotechnology</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

